A preclinical study on T-ALL indicated that the splicing factor SF3B1 inhibitor E7107, when used in combination with chemotherapy drugs, exhibits a promising synergistic antitumor effect [24]. Here, SLU7 is linked to acute lymphoblastic leukemia.